Project Grant F31CA310315
Award Date 1/31/27
Completion Date 7/31/29
Dollars Obligated $100K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New Haven, CT 06511, USA
Similar Awards
- The National Cancer Institute awarded Yale University $142,635 under the Cancer Research Manpower program (CFDA 93.398) on June 3, 2026, to support research decoding long noncoding RNA networks in lineage plasticity and androgen receptor-targeted therapy resistance in prostate cancer. The research employs genome-wide CRISPR interference screening targeting approximately 10,000 long noncoding RNAs to identify mechanisms driving resistance to androgen receptor-targeted therapies in metastatic...
- The National Cancer Institute awarded Yale University $100,228 on December 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research training and biomedical career development in cancer research. Yale will conduct basic research on the regulation of membrane-chromatin interactions during mitotic nuclear formation and their role in cancer cell survival. The project investigates how endoplasmic reticulum membranes and LEM-domain proteins, including LEMD2 and emerin,...
- The National Cancer Institute awarded Yale University $560,087 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to define and target mechanisms of the neurolysin-KIF11-WNT3A axis driving therapy resistance in prostate cancer. The award funds research into how prostate cancer cells adapt to androgen receptor-targeted therapies and remodel the tumor microenvironment to undermine therapeutic activity. The work will comprehensively define the molecular mechanisms by...
- The National Cancer Institute awarded Yale University $149,190 under the Cancer Research Manpower program (CFDA 93.398) on January 15, 2026, to support research investigating the role of N6-methyladenosine (M6A) in the development of drug resistance in glioblastoma. The research characterizes molecular mechanisms by which M6A, the most prevalent internal RNA modification in eukaryotic messenger RNA, regulates glioblastoma pathogenesis and explores how manipulation of M6A regulation may improve...
- The National Cancer Institute awarded Yale University $226,884 under the Cancer Research Manpower program (CFDA 93.398) on January 16, 2026, to support research training in cancer science. The award funds investigation into the role of aberrant m5C mRNA modification in translation initiation and cancer, with the recipient conducting screening of approximately 35,000 human endogenous 5′-untranslated region sequences from multiple tissues to identify m5C installation targets by NSUN2 and NSUN6...
- The National Cancer Institute awarded Yale University $130,490 on June 1, 2026, to support research on cellular and molecular mechanisms of early-onset colorectal cancer under the Cancer Research Manpower program (CFDA 93.398). The award is a Project Grant with a period of performance through May 31, 2028, and work is performed in New Haven, Connecticut. The Cancer Research Manpower program provides biomedical training opportunities for individuals pursuing careers in basic, clinical, and...
- The National Institutes of Health National Cancer Institute awarded Yale University $149,190 on December 27, 2025, under the Cancer Research Manpower program (CFDA 93.398) to support training and research in basic, clinical, and prevention research important to the National Cancer Program. The funded work investigates the anti-tumor roles of tumor-draining lymph nodes in renal cell carcinoma, examining how CD8+ T cells—critical mediators of anti-tumor immunity—differentiate and sustain immune...
- The National Cancer Institute awarded Yale University $149,190 under the Cancer Research Manpower program (CFDA 93.398) on December 24, 2025, to support research training in basic, clinical, and prevention research important to the National Cancer Program. The award funds investigation into the mechanisms of poly (ADP-ribose) polymerase inhibitor (PARPI) cytotoxicity in BRCA1-deficient cancer cells. The research examines two opposing cellular outcomes in response to PARPI treatment:...
- The National Cancer Institute awarded Yale University $100,228 on December 15, 2026, under the Cancer Research Manpower program (CFDA 93.398) to conduct observational studies on immune checkpoint inhibitor utilization, outcomes, and costs in advanced non-small cell lung cancer patients with preexisting autoimmune diseases. The research generates population-based evidence through three aims using real-world insurance claims data. Aim 1 analyzes MarketScan research databases to evaluate the...
- The National Cancer Institute awarded New York University School of Medicine $580,131 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate the cellular properties and pathogenesis of double-null prostate cancer through genetically engineered mouse models and analysis of human castration-resistant prostate cancer data. The research examines how aberrant co-activation of HGF/MET and WNT/β-catenin signaling pathways induces prostate tumor growth and...